TScan Therapeutics (United States)
Our lead TCR-T therapy candidate, TSC-101, is in development for the treatment of patients with hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) (the Phase 1 ALLOHA™ trial, NCT05473910). TSC-101 is administered after allogeneic bone marrow transplantation (hematopoietic cell transplantation or HCT) and has been designed to target residual disease and prevent relapse post-HCT. The Company has also developed multiple TCR-T cell therapy candidates
Basic Information
- Category: business
- Website: https://www.tscan.com/
Documented Facts
- Email: info@tscan.com (No linked source recorded for this statement.)
Evidence and Sources
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about TScan Therapeutics (United States).
- Canonical profile: https://brandsource.ai/brands/tscan-therapeutics-united-states
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/tscan-therapeutics-united-states/json-ld
- Citation profile API: https://brandsource.ai/api/brands/tscan-therapeutics-united-states/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (81/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-21
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Our lead TCR-T therapy candidate, TSC-101, is in development for the treatment of patients with hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) (the Phase 1 ALLOHA™ trial, NCT05473910). TSC-101 is administered after allogeneic bone marrow transplantation (hematopoietic cell transplantation or HCT) and has been designed to target residual disease and prevent relapse post-HCT. The Company has also developed multiple TCR-T cell therapy candidates
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 supporting source linked.
- 1 structured fact available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.